502767-47-7

Upstream product

• 108-77-0 1,3,5-trichloro-2,4,6-triazine 
• 5452-35-7 cycloheptanamine 
• 366-99-4 3-fluoro-4-methoxyaniline 
• 502767-45-5 (4,6-dichloro-[1,3,5]triazin-2-yl)-(3-fluoro-4-methoxy-phenyl)-amine 

Downstream Products

• 676360-58-0 N-(1-benzyl-piperidin-4-yl)-N'-(3-fluoro-4-methoxy-phenyl)-N-cycloheptyl-[1,3,5]triazine-2,4,6-triamine 
• 502767-55-7 N₂-cycloheptyl-N₄-((S)-1-ethyl-pyrrolidin-2-ylmethyl)-N₆-(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine 
• 502767-14-8 N₂-cycloheptyl-N₄-[2-(dimethylamino)ethyl]-N₆-(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine 
• 502767-71-7 N₂-cycloheptyl-N₄-(3-fluoro-4-methoxy-phenyl)-N₆-methyl-N₆-piperidin-4-yl-1,3,5-triazine-2,4,6-triamine 
• 502767-70-6 N₂-cycloheptyl-N₄-(3-fluoro-4-methoxy-phenyl)-N₆-methyl-N₆-(1-methyl-piperidin-4-yl)-1,3,5-triazine-2,4,6-triamine 
• 502766-72-5 N₂-ethyl-N₄-[(1-ethyl-2-pyrrolidinyl)methyl]-N₆-(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine 
• 502766-97-4 N-cycloheptyl-N'-ethyl-N-(3-fluoro-4-methoxy-phenyl)-[1,3,5]triazine-2,4,6-triamine 
• 502767-56-8 N₂-cycloheptyl-N₄-((R)-1-ethyl-pyrrolidin-2-ylmethyl)-N₆-(3-fluoro-4-methoxyphenyl)-1,3,5-triazine-2,4,6-triamine 

Relevant academic research and scientific papers

Triazine compounds and their analogs, compositions, and methods

The present invention relates to triazine compounds and their analogs and derivatives, and methods and compositions comprising these compounds. The compounds and compositions of this invention are useful for, among other things, treating pathophysiological conditions arising from inflammatory responses, inhibiting or blocking glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells, inhibiting smooth muscle proliferation, treating vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis, and the like.

Methods and compositions of novel triazine compounds

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

METHODS AND COMPOSITIONS OF NOVEL TRIAZINE COMPOUNDS

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

Methods and compositions of novel triazine compounds

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

Methods and compositions of novel triazine compounds

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.

Methods and compositions of novel triazine compounds

The present invention relates to methods and compositions comprising compounds that treat pathophysiological conditions arising from inflammatory responses. In particular, the present invention is directed to compounds that inhibit or block glycated protein produced induction of the signaling-associated inflammatory response in endothelial cells. The present invention relates to compounds that inhibit smooth muscle proliferation. In particular, the present invention is directed to compounds that inhibit smooth muscle cell proliferation by modulating HSPGs such as Perlecan. The present invention further relates to the use of compounds to treat vascular occlusive conditions characterized by smooth muscle proliferation such as restenosis and atherosclerosis.